^
Association details:
| Biomarker: | EGFR mutation + TP53 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | Tyrosine kinase inhibitor |
| Direction: | Resistant |
Evidence:
Source:
Title:
Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma
Excerpt:
The clinical data of 36 NSCLC patients with EGFR mutation who received TKI treatment were retrospectively analyzed….All of the patients harbored actionable sensitive EGFR mutations by NGS, with the major types being 19del or 21L858R (52.78%, 19/36 and 55.56%, 20/36, respectively). The 3 most frequent accompanying somatic mutations were TP53 (12, 48.4%), KRAS (7, 19.44%) and PIK3CA (3, 8.33%)...Concomitant mutations were significantly related to lower objective response rates (43.75% vs. 80.0%; P=0.024) and poorer PFS (P<0.001).
DOI:
10.21037/tlcr-20-679
